A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections
Courtney Luterbach, Hongqiang Qiu, Patrick O. Hanafin, Rajnikant Sharma, Joseph Piscitelli, Feng‐Chang Lin, Jenni Ilomäki, Eric Cober, Robert A. Salata, Robert C. Kalayjian, Richard Watkins, Yohei Doi, Keith S. Kaye, Roger L. Nation, Robert A. Bonomo, Cornelia B. Landersdorfer, David van Duin, Gauri G. Rao
Abstract
Antimicrobial resistance is a global threat. As “proof-of-concept,” we employed a system-based approach to identify patient, bacterial, and drug variables contributing to mortality in patients with carbapenem-resistant Klebsiella pneumoniae (CR Kp ) bloodstream infections exposed to colistin (COL) and ceftazidime-avibactam (CAZ/AVI) as mono- or combination therapies.
Topics & Concepts
Klebsiella pneumoniaeColistinDrug resistanceAcinetobacter baumanniiMicrobiologyCarbapenemCeftazidimeMedicineBiologyAntimicrobialAntibioticsPseudomonas aeruginosaBacteriaEscherichia coliBiochemistryGeneGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance